• Leonard spent his first 10 years working for Cooper Laboratories, starting in sales and rising into positions of strategic planning, then acquisitions and eventually head of one of the Cooper divisions. Cooper built its brand as an expert in developing medical specialty silos – acquiring companies and building business units around their medical specialties.
• He put together the first strategic plan and got the first unit operational, which was in the ophthalmology space. In a matter of roughly seven years, the unit went from acquiring a tiny prescription eye-drop company to about $800M in revenue as one of the largest eye care companies in the world, called Cooper Vision.
• Mazur was involved in many of Cooper’s approximately 150 acquisitions and assisted in the creation of Cooper Dermatology, which had Aveeno as one of its flagship products.
• During Mazur’s tenure, Cooper also launched Cooper Dental, which started by acquiring an upstart toothbrush company doing less than $1.0 million in annual sales that it grew into Oral-B, the best selling toothbrush in the world that was bought by Gillette in 1984 for $118.5M.
• From Cooper, he took the job as Director of Marketing at the BASF company Knoll Pharmaceuticals where he launched the painkiller Vicodin, amongst other strong sellers. Following Knoll, Mazur moved on to ICN Pharmaceuticals, now called Valeant Pharmaceuticals. As VP of Sales and Marketing at ICN, Mazur launched Ribavirin, a staple in treating hepatitis C and other maladies.
• He became EVP at the microcap startup Medicis Pharmaceutical, where he successfully created and launched Dynacin, a drug with minocycline in it that became one of the best-known branded generics of all time. In 2012, Valeant acquired Medicis for $2.6B.
• He created dermatology company Genesis Pharmaceutical in 1995 and selling it to French specialty pharma Pierre Fabre in 2003 and then founding Triax Pharmaceuticals (sold to PreCision Dermatology in 2012, which was acquired by Valeant in 2014 for $475 million) and Akrimax Pharmaceuticals (~$100M in sales before pieces started being acquired).

The takeaway from this list is that Mr. Mazur has extensive experience in launching & creating strong brands and is familiar in the M&A space.

• Co-founder, director and CEO of Leonard Meron Biosciences, Inc. prior to its merger with Citius in March 2016
• President of Roche Laboratories, Inc. (“Roche”), a major research-based pharmaceutical company, from December 1998 to August 2001
• President of Roche, Mr. Holubiak helped transform Roche Labs into a leading antibiotic and biotechnology company
• Founder of Emron, Inc., a health economics and managed care consulting company, and helped to create the Academy of Managed Care Pharmacy (AMCP)
• Director of Bioscrip, Inc., a national home infusion company, from 2002 through 2016, and served as its Chairman of the Board from 2012 through 2016
• Since July 2010, Mr. Holubiak has served as a member of the Board of Directors of Assembly Biosciences, Inc. and its predecessor, Ventrus Biosciences, Inc.

• Recent Therapeutic Area Head and Vice President of the Clinical Research and Development Global Lymphoma/CLL Program at Celgene
• Former Chief, Lymphoma/Myeloma service at Roswell Park Comprehensive Cancer Center in Buffalo
• Published more than 180 peer-reviewed journal articles